JAK Mutations as Escape Mechanisms to Anti–PD-1 Therapy

Summary: JAK mutations could be one of the primary escape mechanisms to anti–PD-1/PD-L1 immunotherapy via impaired IFNγ signaling in cancer cells and could be used to identify patients unlikely to benefit from these treatments.